Please assess the completion status of the following clinical trial:

Trial Title: Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients registered in the Zhejiang Stroke Quality Control Centre (ZSQCC) platform from Jan 2017 to Mar 2020~* \> 80 years of age~* Diagnosed with AIS at admission~* Arrived or admitted to the hospital within 4.5 hours of symptom onset~* If treated with IV rt-PA: received IV rt-PA within 4.5 hours of symptom onset~Exclusion criteria:~* Documented Intravenous Thrombolysis (IVT) contraindication except age to IV rt-PA treatment according to the Summary of Product Characteristics (SmPC)~* Missing any one of the key data (age, gender, baseline National Institutes of Health Stroke Scale \[NIHSS\], time of symptom onset, time of hospital arrival or admission, IVT or not, time of IV rt-PA treatment)~* Received thrombolysis agents other than rt-PA (urokinase, tenecteplase, recombinant plasminogen activator, prourokinase, streptokinase)~* Received endovascular treatment~* Received IV rt-PA after 4.5 hours of symptom onset

- Gender: ALL
- Minimum Age: 80 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV rt-PA cohort (Type: None): Acute Ischaemic Stroke (AIS) patients aged \> 80 years who received intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) (Alteplase) within 4.5 hours of symptom onset
- Non-reperfusion cohort (Type: None): Acute Ischaemic Stroke (AIS) patients aged \> 80 years who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive any reperfusion treatments

Based on this trial design, predict the completion outcome and termination type (if applicable).